References
- R. Loomba, S. L. Friedman and G. I. Shulman, Mechanisms and disease consequences of nonalcoholic fatty liver disease, Cell 184(10) (2021) 2537–2564; https://doi.org/10.1016/j.cell.2021.04.015
- F. Bessone, M. V. Razori and M. G. Roma, Molecular pathways of nonalcoholic fatty liver disease development and progression, Cell. Mol. Life Sci. 76(1) (2019) 99–128; https://doi.org/10.1007/s00018-018-2942-5
- M. Papatheodoridi and E. Cholongitas, Diagnosis of non-alcoholic fatty liver disease (NAFLD): Current concepts, Curr. Pharm. Des. 24(38) (2018) 4574–4586; https://doi.org/10.2174/1381612824666181002105543
- C. D. Byrne and G. Targher, NAFLD: A multisystem disease, J. Hepatol. 62(1)(Suppl.) (2015) S47–S64; https://doi.org/10.1016/j.jhep.2014.12.012
- A. Vadarlis, C. Antza, D. R. Bakaloudi, I. Doundoulakis, G. Kalopitas, M. Samara, T. Dardavessis, T. Maris and M. Chourdakis, Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease, J. Gastroenterol. Hepatol. 36(2) (2021) 311–319; https://doi.org/10.1111/jgh.15221
- M. Y. Wang, K. Prabahar, M. A. Găman and J. L. Zhang, Vitamin E supplementation in the treatment of nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials, J. Dig. Dis. 24(6–7) (2023) 380–389; https://doi.org/10.1111/1751-2980.13210
- C. Gofton, Y. Upendran, M. H. Zheng and J. George, MAFLD: How is it different from NAFLD?, Clin. Mol. Hepatol. 29(Suppl) (2023) S17–S31; https://doi.org/10.3350/cmh.2022.0367
- S. L. Friedman, B. A. Neuschwander-Tetri, M. Rinella and A. J. Sanyal, Mechanisms of NAFLD development and therapeutic strategies, Nat. Med. 24(7) (2018) 908–922; https://doi.org/10.1038/s41591-018-0104-9
- L. Rong, J. Zou, W. Ran, X. Qi, Y. Chen, H. Cui and J. Guo, Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD), Front. Endocrinol. (Lausanne) 13 (2023) Article ID 1087260 (18 pages); https://doi.org/10.3389/fendo.2022.1087260
- M. J. Watt, P. M. Miotto, W. De Nardo and M. K. Montgomery, The liver as an endocrine organ – Linking NAFLD and insulin resistance, Endocr. Rev. 40(5) (2019) 1367–1393; https://doi.org/10.1210/er.2018-00241
- Y. Sakurai, N. Kubota, T. Yamauchi and T. Kadowaki, Role of insulin resistance in MAFLD, Int. J. Mol. Sci. 22(8) (2021) Article ID 4156 (26 pages); https://doi.org/10.3390/ijms22084156
- G. Paradies, V. Paradies, F. M. Ruggiero and G. Petrosillo, Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease, World J. Gastroenterol. 20(39) (2014) 14205–14218; https://doi.org/10.3748/wjg.v20.i39.14205
- J. Yang, M. Fernández-Galilea, L. Martínez-Fernández, P. González-Muniesa, A. Pérez-Chávez, J. A. Martínez and M. J. Moreno-Aliaga, Oxidative stress and non-alcoholic fatty liver disease: Effects of omega-3 fatty acid supplementation, Nutrients 11(4) (2019) Article ID 872 (37 pages); https://doi.org/10.3390/nu11040872
- C. Luci, M. Bourinet, P. S. Leclère, R. Anty and P. Gual, Chronic inflammation in non-alcoholic steatohepatitis: Molecular mechanisms and therapeutic strategies, Front. Endocrinol. (Lausanne) 11 (2020) Article ID 597648 (14 pages); https://doi.org/10.3389/fendo.2020.597648
- R. Forlano, B. H. Mullish, S. K. Mukherjee, R. Nathwani, C. Harlow, P. Crook, R. Judge, A. Soubieres, P. Middleton, A. Daunt, P. Perez-Guzman, N. Selvapatt, M. Lemoine, A. Dhar, M. R. Thursz, S. Nayagam and P. Manousou, In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19, PLoS One 15(10) (2020) e0240400; https://doi.org/10.1371/journal.pone.0240400.
- A. A. Kolodziejczyk, D. Zheng, O. Shibolet and E. Elinav, The role of the microbiome in NAFLD and NASH, EMBO Mol. Med. 11(2) (2019) e9302; https://doi.org/10.15252/emmm.201809302
- A. Albillos, A. de Gottardi and M. Rescigno, The gut-liver axis in liver disease: Pathophysiological basis for therapy, J. Hepatol. 72(3) (2020) 558–577; https://doi.org/10.1016/j.jhep.2019.11.003
- Z. Younossi, Q. M. Anstee, M. Marietti, T. Hardy, L. Henry, M. Eslam, J. George and E. Bugianesi, Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention, Nat. Rev. Gastroenterol. Hepatol. 15(1) (2018) 11–20; https://doi.org/10.1038/nrgastro.2017.109
- S. Wei, L. Wang, P. C. Evans and S. Xu, NAFLD and NASH: Etiology, targets and emerging therapies, Drug Discov. Today 29(3) (2024) Article ID 103910; https://doi.org/10.1016/j.drudis.2024.103910
- Y. Sun, Y. Ma, F. Sun, W. Feng, H. Ye, T. Tian and M. Lei, Astragaloside IV attenuates lipopolysaccharide induced liver injury by modulating Nrf2-mediated oxidative stress and NLRP3-mediated inflammation, Heliyon 9(4) (2023) e15436; https://doi.org/10.1016/j.heliyon.2023.e15436
- S. Wu, F. Wen, X. Zhong, W. Du, M. Chen and J. Wang, Astragaloside IV ameliorate acute alcohol-induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway, Ann. Med. 55(1) (2023) Article ID 2216942 (16 pages); https://doi.org/10.1080/07853890.2023.2216942
- Y. Li, X. Yang, X. Li, S. Wang, P. Chen, T. Ma and B. Zhang, Astragaloside IV and cycloastragenol promote liver regeneration through regulation of hepatic oxidative homeostasis and glucose/lipid metabolism, Phytomedicine 135 (2024) Article ID 156165; https://doi.org/10.1016/j.phymed.2024.156165
- B. Zhou, D. L. Zhou, X. H. Wei, R. Y. Zhong, J. Xu and L. Sun, Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation, Acta Pharmacol. Sin. 38(7) (2017) 998–1008; https://doi.org/10.1038/aps.2016.175
- Y. Zhai, W. Zhou, X. Yan, Y. Qiao, L. Guan, Z. Zhang, H. Liu, J. Jiang, J. Liu and L. Peng, Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling, Phytomedicine 107 (2022) Article ID 154444; https://doi.org/10.1016/j.phymed.2022.154444
- Y.-L. Liu, Q.-Z. Zhang, Y.-R. Wang, L.-N. Fu, J.-S. Han, J. Zhang and B.-M. Wang, Astragaloside IV improves high-fat diet-induced hepatic steatosis in nonalcoholic fatty liver disease rats by regulating inflammatory factors level via TLR4/NF-κB signaling pathway, Front. Pharmacol. 11 (2021) Article ID 605064 (11 pages); https://doi.org/10.3389/fphar.2020.605064
- J. M. Clark, Weight loss as a treatment for nonalcoholic fatty liver disease, J. Clin. Gastroenterol. 40(Suppl. 1) (2006) S39–S43; https://doi.org/10.1097/01.mcg.0000168641.31321.fa
- N. Hossain, P. Kanwar and S. R. Mohanty, A comprehensive updated review of pharmaceutical and nonpharmaceutical treatment for NAFLD, Gastroenterol. Res. Pract. 2016 (2016) Article ID 7109270 (17 pages); https://doi.org/10.1155/2016/7109270
- S. Pouwels, N. Sakran, Y. Graham, A. Leal, T. Pintar, W. Yang, R. Kassir, R. Singhal, K. Mahawar and D. Ramnarain, Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss, BMC Endocr. Disord. 22(1) (2022) Article ID 63 (9 pages); https://doi.org/10.1186/s12902-022-00980-1
- M. F. Abdelmalek, Nonalcoholic fatty liver disease: Another leap forward, Nat. Rev. Gastroenterol. Hepatol. 18(2) (2021) 85–86; https://doi.org/10.1038/s41575-020-00406-0
- G. Farrell, Insulin resistance, obesity, and liver cancer, Clin. Gastroenterol. Hepatol. 12(1) (2014) 117–119; https://doi.org/10.1016/j.cgh.2013.07.040
- N. Sodum, G. Kumar, S. L. Bojja, N. Kumar and C. M. Rao, Epigenetics in NAFLD/NASH: Targets and therapy, Pharmacol. Res. 167 (2021) Article ID 105484; https://doi.org/10.1016/j.phrs.2021.105484
- S. A. Harrison, A. M. Allen, J. Dubourg, M. Noureddin and N. Alkhouri, Challenges and opportunities in NASH drug development, Nat. Med. 29(3) (2023) 562–573; https://doi.org/10.1038/s41591-023-02242-6
- S. J. Song, J. C. T. Lai, G. L. H. Wong, V. W. S. Wong and T. C. F. Yip, Can we use old NAFLD data under the new MASLD definition?, J. Hepatol. 80(2) (2024) e54–e56; https://doi.org/10.1016/j.jhep.2023.07.021
- R. Younes and E. Bugianesi, The impact of metabolic syndrome on the outcome of NASH: Cirrhosis, hepatocellular carcinoma, and mortality, Curr. Hepatol. Rep. 17(4) (2018) 336–344; https://doi.org/10.1007/s11901-018-0422-x
- T. Puengel and F. Tacke, Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH), Expert Opin. Investig. Drugs 32(6) (2023) 451–461; https://doi.org/10.1080/13543784.2023.2230115
- K. Shree Harini and D. Ezhilarasan, Wnt/β-catenin signaling and its modulators in nonalcoholic fatty liver diseases, Hepatobiliary Pancreat. Dis. Int. 22(4) (2023) 333–345; https://doi.org/10.1016/j.hbpd.2022.10.003
- N. Bhala, R. Younes and E. Bugianesi, Epidemiology and natural history of patients with NAFLD, Curr. Pharm. Des. 19(29) (2013) 5169–5176; https://doi.org/10.2174/13816128113199990336
- H. Kojima, S. Sakurai, M. Uemura, H. Fukui, H. Morimoto and Y. Tamagawa, Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis, Alcohol Clin. Exp. Res. 31(s1) (2007) S61– S66; https://doi.org/10.1111/j.1530-0277.2006.00288.x
- N. Alkhouri, M. P. Berk, R. Lopez, T. Abu-Rajab Tamimi, L. Yerian, Y. Chung, R. Zhang, T. M. Mc-Intyre, S. L. Hazen and A. E. Feldstein, OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease, Dig. Dis. Sci. 59(7) (2014) 1617–1624; https://doi.org/10.1007/s10620-014-3031-8
- L. S. R. R. Okada, C. P. Oliveira, J. T. Stefano, M. A. Nogueira, I. D. C. G. da Silva, F. B. Cordeiro, V. A. F. Alves, R. S. Torrinhas, F. J. Carrilho, P. Puri and D. L. Waitzberg, Omega-3 PUFA modulate lipo-genesis, ER stress, and mitochondrial dysfunction markers in NASH – proteomic and lipidomic insight, Clin. Nutr. 37(5) (2017) 1474–1484; https://doi.org/10.1016/j.clnu.2017.08.031
- J. S. Chang, J. H. Ahn, S. H. Kang, S. B. Koh, J. Y. Kim, S. K. Baik, J. H. Huh, S. S. Lee, M. Y. Kim and K. S. Park, Metabolic stress index including mitochondrial biomarker for noninvasive diagnosis of hepatic steatosis, Front. Endocrinol. 13 (2022) Article ID 896334 (8 pages); https://doi.org/10.3389/fendo.2022.896334
- S. Seki, T. Kitada and H. Sakaguchi, Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases, Hepatol. Res. 33(2) (2005) 132–134; https://doi.org/10.1016/j.hepres.2005.09.020
- J. Zhang, C. Wu, L. Gao, G. Du and X. Qin, Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects, Adv. Pharmacol. 87 (2020) 89–112; https://doi.org/10.1016/bs.apha.2019.08.002
- L. Li, X. Hou, R. Xu, C. Liu and M. Tu, Research review on the pharmacological effects of astragalo-side IV, Fundam. Clin. Pharmacol. 31(1) (2017) 17–36; https://doi.org/10.1111/fcp.12232
- Z. Zhuang, Z.-H. Wang, L.-H. Deng, Q. Zheng, G.-Q. Zheng and Y. Wang, Astragaloside IV exerts cardioprotection in animal models of viral myocarditis: A preclinical systematic review and meta-analysis, Front. Pharmacol. 10 (2019) Article ID 1388 (11 pages); https://doi.org/10.3389/fphar.2019.01388
- F. Xu, W. Q. Cui, Y. Wei, J. Cui, J. Qiu, L. L. Hu, W. Y. Gong, J. C. Dong and B. J. Liu, Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling, J. Exp. Clin. Cancer Res. 37(1) (2018) Article ID 207 (16 pages); https://doi.org/10.1186/s13046-018-0878-0
- Z. Han, J. Zhu and Z. Han, Evaluation of astragaloside IV in hepatic fibrosis: A meta-analysis, Medicine 100(13) (2021) e25105; https://doi.org/10.1097/MD.0000000000025105
- H. Wang, Z. Zhuang, Y.-Y. Huang, Y. Zhuang, J. Jin, X. Ye, Z. Lin, J. Zheng and H. Wang, Protective effect and possible mechanisms of astragaloside IV in animal models of diabetic nephropathy: A preclinical systematic review and meta-analysis, Front. Pharmacol. 11 (2020) Article ID 988 (17 pages); https://doi.org/10.3389/fphar.2020.00988
- I. M. Costa, F. O. V. Lima, L. C. B. Fernandes, B. Norrara, F. I. Neta, R. D. Alves, J. R. L. P. Cavalcanti, E. E. S. Lucena, J. S. Cavalcante, A. C. M. Rego, I. A. Filho, D. B. Queiroz, M. A. M. Freire and F. P. Guzen, Astragaloside IV supplementation promotes a neuroprotective effect in experimental models of neurological disorders: A systematic review, Curr. Neuropharmacol. 17(7) (2019) 648–665; https://doi.org/10.2174/1570159X16666180911123341
- M. Marušić, M. Paić, M. Knobloch and A.-M. Liberati Pršo, NAFLD, insulin resistance, and diabetes mellitus type 2, Can. J. Gastroenterol. Hepatol. 2021 (2021) Article ID 6613827 (9 pages); https://doi.org/10.1155/2021/6613827
- D. Xia, W. Li, C. Tang and J. Jiang, Astragaloside IV, as a potential anticancer agent, Front. Pharmacol. 14 (2023) Article ID 1065505 (15 pages); https://doi.org/10.3389/fphar.2023.1065505
- K. Mehta, D. H. Van Thiel, N. Shah and S. Mobarhan, Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants, Nutr. Rev. 60(9) (2002) 289–293; https://doi.org/10.1301/002966402320387224
- F. Item, S. Wueest, V. Lemos, S. Stein, F. C. Lucchini, R. Denzler, M. C. Fisser, T. D. Challa, E. Pirinen, Y. Kim, S. Hemmi, E. Gulbins, A. Gross, L. A. O’Reilly, M. Stoffel, J. Auwerx and D. Konrad, Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function, Nat. Commun. 8(1) (2017) Article ID 480 (10 pages); https://doi.org/10.1038/s41467-017-00566-9
- L. Ding, W. Sun, M. Balaz, A. He, M. Klug, S. Wieland, R. Caiazzo, V. Raverdy, F. Pattou, P. Lefebvre, I. J. Lodhi, B. Staels, M. Heim and C. Wolfrum, Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis, Nat. Metab. 3(12) (2021) 1648–1661; https://doi.org/10.1038/s42255-021-00489-2
- X. Zhou, L. L. Wang, W. J. Tang and B. Tang, Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells, J. Ethnopharmacol. 268(11) (2021) Article ID 113556; https://doi.org/10.1016/j.jep.2020.113556
- J. L. Rains and S. K. Jain, Oxidative stress, insulin signaling, and diabetes, Free Radic. Biol. Med. 50(5) (2011) 567–575; https://doi.org/10.1016/j.freeradbiomed.2010.12.006
- S. Vomund, A. Schäfer, M. J. Parnham, B. Brüne and A. Von Knethen, Nrf2, the master regulator of anti-oxidative responses, Int. J. Mol. Sci. 18(12) (2017) Article ID 2772 (19 pages); https://doi.org/10.3390/ijms18122772
- S. Herzig and R. J. Shaw, AMPK: Guardian of metabolism and mitochondrial homeostasis, Nat. Rev. Mol. Cell Biol. 19(2) (2018) 121–135; https://doi.org/10.1038/nrm.2017.95
- H. Yun, S. Park, M. J. Kim, W. K. Yang, D. U. Im, K. R. Yang, J. Hong, W. Choe, I. Kang, S. S. Kim and J. Ha, AMP-activated protein kinase mediates the antioxidant effects of resveratrol through regulation of the transcription factor FoxO1, FEBS J. 281(19) (2014) 4421–4438; https://doi.org/10.1111/febs.12949
- Q. Lu, L. Yang, J.-J. Xiao, Q. Liu, L. Ni, J.-W. Hu, H. Yu, X. Wu and B.-F. Zhang, Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway, Free Radic. Biol. Med. 195 (2023) 89–102; https://doi.org/10.1016/j.freeradbiomed.2022.12.088
- X. Li, D. Wu and T. Ye, Fibroblast growth factor 19 protects the heart from oxidative stress-induced diabetic cardiomyopathy via activation of AMPK/Nrf2/HO-1 pathway, Biochem. Biophys. Res. Commun. 502(1) (2018) 62–68; https://doi.org/10.1016/j.bbrc.2018.05.121
- X. H. Zhou, L. Q. He, S. N. Zuo, Y. M. Zhang, D. Wan, C. M. Long, P. Huang, X. Wu, C. R. Wu, G. Liu and Y. Yin, Serine prevented high-fat diet–induced oxidative stress by activating AMPK and epigenetically modulating the expression of glutathione synthesis-related genes, Biochim. Biophys. Acta Mol. Basis Dis. 1864(2) (2018) 488–498; https://doi.org/10.1016/j.bbadis.2017.11.009
- L. Li, W. X. Huang, S. K. Wang, K. Sun, W. Zhang, Y. Ding, L. Zhang, B. Tumen and L. Lang, Astragaloside IV attenuates acetaminophen-induced liver injuries in mice by activating the Nrf2 signaling pathway, Molecules 23(8) (2018) Article ID 2032 (9 pages); https://doi.org/10.3390/molecules23082032
- N. Cheng, S. Chen, X. Liu, H. Zhao and W. Cao, Impact of Schisandra chinensis bee pollen on non-alcoholic fatty liver disease and gut microbiota in high-fat diet induced obese mice, Nutrients 11(2) (2019) Article ID 346 (16 pages); https://doi.org/10.3390/nu11020346
- M. Martin, K. Rehani, R. S. Jope and S. M. Michalek, Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3, Nat. Immunol. 6(8) (2005) 777–784; https://doi.org/10.1038/ni1221
- D. Sag, D. Carling, R. D. Stout and J. Suttles, Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype, J. Immunol. 181(12) (2008) 8633–8641; https://doi.org/10.4049/jimmunol.181.12.8633
- R. Wei, H. Liu, R. Chen, Y. Sheng and T. Liu, Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway, Exp. Ther. Med. 17(1) (2019) 393–397; https://doi.org/10.3892/etm.2018.6966 Spandidos Publications
- D. Qin, D. N. Ma, Z. G. Ren, X. D. Zhu, C. H. Wang, Y. C. Wang, B. Ye, M. Cao, D. Gao, Z. Tang and Z. Tang, Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway, Oncol. Rep. 37(3) (2017) 1725–1735; https://doi.org/10.3892/or.2017.5389
- X. Qu, H. Gao, L. Tao, Y. Zhang, J. Zhai, J. Sun, Y. Song and S. Zhang, Astragaloside IV protects against cisplatin-induced liver and kidney injury via autophagy-mediated inhibition of NLRP3 in rats, J. Toxicol. Sci. 44(3) (2019) 167–175; https://doi.org/10.2131/jts.44.167
- J. R. Ham, H.-I. Lee, R.-Y. Choi, M.-O. Sim, K.-I. Seo and M.-K. Lee, Anti-steatotic and anti-inflammatory roles of syringic acid in high-fat diet-induced obese mice, Food Funct. 7(2) (2016) 689–697; https://doi.org/10.1039/C5FO01411A
- G. Baffy, Kupffer cells in non-alcoholic fatty liver disease: The emerging view, J. Hepatol. 51(1) (2009) 212–223; https://doi.org/10.1016/j.jhep.2009.03.008
- S. Saravanan, V. I. Islam, N. P. Babu, P. Pandikumar, K. Thirugnanasambantham, M. Chellappandian, C. S. Raj, M. G. Paulraj and S. Ignacimuthu, Swertiamarin attenuates inflammation mediators via modulating NF-κB/IκB and JAK2/STAT3 transcription factors in adjuvant induced arthritis, Eur. J. Pharm. Sci. 56 (2014) 70–86; https://doi.org/10.1016/j.ejps.2014.02.005
- Z. L. Bian, Y. Peng, Z. You, Q. Wang, Q. Miao, Y. Liu, X. Han, D. Qiu, Z. Li and X. Ma, CCN1 expression in hepatocytes contributes to macrophage infiltration in nonalcoholic fatty liver disease in mice, J. Lipid Res. 54(1) (2013) 44–54; https://doi.org/10.1194/jlr.M026013
- E. Radi, P. Formichi, C. Battisti and A. Federico, Apoptosis and oxidative stress in neurodegenerative diseases, J. Alzheimer’s Dis. 42(Suppl. 3) (2014) S125–S152; https://doi.org/10.3233/JAD-132738
- K. J. Campbell and S. W. G. Tait, Targeting BCL-2 regulated apoptosis in cancer, Open Biol. 8(5) (2018) Article ID 180002 (11 pages); https://doi.org/10.1098/rsob.180002
- C. A. Gregory, H. Singh, A. S. Perry and D. J. Prockop, Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion, J. Biol. Chem. 278(22) (2003) 19732–19742; https://doi.org/10.1074/jbc.M300373200
- C. Cárdenas, R. A. Miller, I. Smith, T. Bui, J. Molgó, M. Müller, H. Vais, K.-H. Cheung, J. Yang, I. Parker, C. B. Thompson, M. J. Birnbaum, K. R. Hallows and J. K. Foskett, Essential regulation of cell bioenergetics by constitutive InsP₃ receptor Ca²⁺ transfer to mitochondria, Cell 142(2) (2010) 270–283; https://doi.org/10.1016/j.cell.2010.06.007
- J. A. Martinez, Z. Zhang, S. I. Svetlov, R. L. Hayes, K. K. Wang and S. F. Larner, Calpain and caspase processing of caspase-12 contribute to the ER stress-induced cell death pathway in differentiated PC12 cells, Apoptosis 15(12) (2010) 1480–1493; https://doi.org/10.1007/s10495-010-0531-7
- C. J. Hanson, M. D. Bootman, C. W. Distelhorst, R. J. H. Wojcikiewicz and H. L. Roderick, Bcl-2 suppresses Ca²⁺ release through inositol 1,4,5-trisphosphate receptors and inhibits Ca²⁺ uptake by mitochondria without affecting ER calcium store content, Cell Calcium 44(3) (2008) 324–338; https://doi.org/10.1016/j.ceca.2008.01.003
- X.-Y. Liang, F.-F. Hong and S.-L. Yang, Astragaloside IV alleviates liver inflammation, oxidative stress and apoptosis to protect against experimental non-alcoholic fatty liver disease, Diabetes Metab. Syndr. Obes. 14 (2021) 1871–1883; https://doi.org/10.2147/DMSO.S304817
- X. Liu, W. Chu, S. Shang, L. Ma, C. Jiang, Y. Ding, J. Wang, S. Zhang and B. Shao, Preliminary study on the anti-apoptotic mechanism of astragaloside IV on radiation-induced brain cells, Int. J. Immunopathol. Pharmacol. 34 (2020) Article ID 2058738420954594; https://doi.org/10.1177/2058738420954594
- Z. Liu, Z. Zhou, P. Ai, C. Zhang, J. Chen and Y. Wang, Astragaloside IV attenuates ferroptosis after subarachnoid hemorrhage via Nrf2/HO-1 signaling pathway, Front. Pharmacol. 13 (2022) Article ID 924826 (13 pages); https://doi.org/10.3389/fphar.2022.924826
- Z. Qi, P. Zhang, L. Yang, P. Song, J. Zhao, H. Wang, Y. Zhao and L. Cao, Astragaloside IV alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte pyroptosis through the SIRT1/NLRP3 pathway, Am. J. Chin. Med. 52(2) (2024) 453–469; https://doi.org/10.1142/S0192415X24500198
- X. Meng, G. Zhang, H. Cao, D. Yu, X. Fang, W. M. de Vos and H. Wu, Gut dysbacteriosis and intestinal disease: Mechanism and treatment, J. Appl. Microbiol. 129(4) (2020) 787–805; https://doi.org/10.1111/jam.14661
- L. L. Deng, Astragaloside IV as potential antioxidant against diabetic ketoacidosis in juvenile mice through activating JNK/Nrf2 signaling pathway, Arch. Med. Res. 51(7) (2020) 654–663; https://doi.org/10.1016/j.arcmed.2020.06.013
- D. M. Chopyk and A. Grakoui, Contribution of the intestinal microbiome and gut barrier to hepatic disorders, Gastroenterology 159(3) (2020) 849–863; https://doi.org/10.1053/j.gastro.2020.04.077
- J. W. Jung, F. Wang, A. Turk, J. S. Park, H. Ma, Y. Ma, H.-R. Noh, G. Sui, D. S. Shin, M. K. Lee and Y. S. Roh, Zaluzanin C alleviates inflammation and lipid accumulation in Kupffer cells and hepatocytes by regulating mitochondrial ROS, Molecules 28(22) (2023) Article ID 7484; https://doi.org/10.3390/molecules28227484
- J. Fang, C.-H. Yu, X.-J. Li, J.-M. Yao, Z.-Y. Fang, S.-H. Yoon and W.-Y. Yu, Gut dysbiosis in nonalcoholic fatty liver disease: Pathogenesis, diagnosis, and therapeutic implications, Front. Cell. Infect. Microbiol. 12 (2022) Article ID 997018 (12 pages); https://doi.org/10.3389/fcimb.2022.997018
- D. Zhang, X. Hao, L. Xu, J. Cui, L. Xue and Z. Tian, Intestinal flora imbalance promotes alcohol- induced liver fibrosis by the TGFβ/Smad signaling pathway in mice, Oncol. Lett. 14(4) (2017) 4511–4516; https://doi.org/10.3892/ol.2017.6762
- A. Wieland, D. N. Frank, B. Harnke and K. Bambha, Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease, Aliment. Pharmacol. Ther. 42(9) (2015) 1051–1063; https://doi.org/10.1111/apt.13376
- L. Xue, Z. Deng, W. Luo, X. He and Y. Chen, Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial, Front. Cell. Infect. Microbiol. 12 (2022) Article ID 759306 (10 pages); https://doi.org/10.3389/fcimb.2022.759306
- V. Kaden-Volynets, M. Basic, U. Neumann, D. Pretz, A. Rings, A. Bleich and S. C. Bischoff, Lack of liver steatosis in germ-free mice following hypercaloric diets, Eur. J. Nutr. 58 (2019) 1933–1945; https://doi.org/10.1007/s00394-018-1748-4
- J. Fu, M. J. Bonder, M. C. Cenit, E. F. Tigchelaar, A. Maatman, J. A. M. Dekens, E. Brandsma, J. Marczynska, F. Imhann, R. K. Weersma, L. Franke, T. W. Poon, R. J. Xavier, D. Gevers, M. H. Hofker, C. Wijmenga and A. Zhernakova, The gut microbiome contributes to a substantial proportion of the variation in blood lipids, Circ. Res. 117(9) (2015) 817–824; https://doi.org/10.1161/CIRCRESAHA.115.306807
- Z. Li, E. Hu, F. Zheng, S. Wang, W. Zhang, J. Luo, T. Tang, Q. Huang and Y. Wang, The effects of astragaloside IV on gut microbiota and serum metabolism in a mice model of intracerebral hemorrhage, Phytomedicine 121 (2023) Article ID 155086; https://doi.org/10.1016/j.phymed.2023.155086
- X. Q. Du, L. P. Shi, Z. W. Chen, J. Y. Hu, B. Zuo, Y. Xiong and W. F. Cao, Astragaloside IV ameliorates isoprenaline-induced cardiac fibrosis in mice via modulating gut microbiota and fecal metabolites, Front. Cell. Infect. Microbiol. 12 (2022) Article ID 836150 (11 pages); https://doi.org/10.3389/fcimb.2022.836150
- T. Yang, S. Xie, L. Cao, M. Li, L. Ding, L. Wang, S. Pang, Z. Wang and L. Geng, Astragaloside IV modulates gut macrophages M1/M2 polarization by reshaping gut microbiota and short chain fatty acids in sepsis, Shock 61(1) (2024) 120–131; https://doi.org/10.1097/SHK.0000000000002262
- P. Golabi, H. Bush, M. Stepanova, C. T. Locklear, J. P. Weston, Z. Goodman, I. M. Younossi and Z. M. Younossi, Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steato-hepatitis (NASH) cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016, Medicine 97(31) (2018) e11518; https://doi.org/10.1097/MD.0000000000011518
- S. A. Harrison, M. R. Bashir, C. D. Guy, R. Zhou, C. A. Moylan, J. P. Frias, N. Alkhouri, M. B. Bansal, S. Baum, B. A. Neuschwander-Tetri, R. Taub and S. E. Moussa, Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo- controlled, phase 2 trial, Lancet 394(10213) (2019) 2012–2024; https://doi.org/10.1016/S0140-6736(19)32517-6
- A. R. Saran, S. Dave and A. Zarrinpar, Circadian rhythms in the pathogenesis and treatment of fatty liver disease, Gastroenterology 158(7) (2020) 1948–1966.e1; https://doi.org/10.1053/j.gastro.2020.01.050
- S. M. Francque, P. Bedossa, V. Ratziu, Q. M. Anstee, E. Bugianesi, A. J. Sanyal, R. Loomba, S. A. Harrison, R. Balabanska, L. Mateva, N. Lanthier, N. Alkhouri, C. Moreno, J. M. Schattenberg, D. Stefanova-Petrova, L. Vonghia, R. Rouzier, M. Guillaume, A. Hodge, M. Romero-Gómez, P. Huot-Marchand, M. Baudin, M.-P. Richard, J.-L. Abitbol, P. Broqua, J.-L. Junien and M. F. Abdelmalek, A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH, N. Engl. J. Med. 385(17) (2021) 1547–1558; https://doi.org/10.1056/NEJMoa2036205
- P. N. Newsome, K. Buchholtz, K. Cusi, M. Linder, T. Okanoue, V. Ratziu, A. J. Sanyal, A.-S. Sejling and S. A. Harrison, A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steato-hepatitis, N. Engl. J. Med. 384(12) (2021) 1113–1124; https://doi.org/10.1056/NEJMoa2028395
- N. Alkhouri, R. Herring, H. Kabler, Z. Kayali, T. Hassanein, A. Kohli, R. S. Huss, Y. Zhu, A. N. Billin, L. H. Damgaard, K. Buchholtz, M. S. Kjær, C. Balendran, R. P. Myers, R. Loomba and M. Noureddin, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial, J. Hepatol. 77(3) (2022) 607–618; https://doi.org/10.1016/j.jhep.2022.04.003
- R. Loomba, E. J. Lawitz, J. P. Frias, G. Ortiz-Lasanta, L. Johansson, B. B. Franey, L. Morrow, M. Rosenstock, C. L. Hartsfield, C.-Y. Chen, L. Tseng, R. W. Charlton, H. Mansbach and M. Margalit, Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study, Lancet Gastroenterol. Hepatol. 8(2) (2023) 120–132; https://doi.org/10.1016/S2468-1253(22)00347-8
- S. A. Harrison, J. P. Frias, G. Neff, G. A. Abrams, K. J. Lucas, W. Sanchez, S. Gogia, M. Y. Sheikh, C. Behling, P. Bedossa, L. Shao, D. Chan, E. Fong, B. de Temple, R. Shringarpure, E. J. Tillman, T. Rolph, A. Cheng and K. Yale, Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial, Lancet Gastroenterol. Hepatol. 8(12) (2023) 1080–1093; https://doi.org/10.1016/S2468-1253(23)00272-8
- J. Zhou, L. R. Waskowicz, A. Lim, X.-H. Liao, B. Lian, H. Masamune, S. Refetoff, B. Tran, D. D. Koeberl and P. M. Yen, A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia, Thyroid 29(8) (2019) 1158–1167; https://doi.org/10.1089/thy.2019.0007
- S. A. Harrison, R. Taub, G. W. Neff, K. J. Lucas, D. Labriola, S. E. Moussa, N. Alkhouri and M. R. Bashir, Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial, Nat. Med. 29(11) (2023) 2919–2928; https://doi.org/10.1038/s41591-023-02603-1
- Chinese Pharmacopoeia Commission, Pharmacopoeia of the People’s Republic of China, 11th ed., China Medical Science Press, Beijing 2020.